Pharmacosmos investigates anemia treatment in new patient group

A new phase III study will shed light on the efficacy of Pharmacosmos's Monoferric/Monofer in children and adolescents. This patient segment has not been eligible for the iron deficiency anemia treatment before.
Photo: Pharmacosmos / PR
Photo: Pharmacosmos / PR
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Danish Pharmacosmos is on the hunt for 200 patients between the ages 0 and 18 for a clinical phase III trial involving intravenous injection treatment Monoferric, also known as Monofer, for iron deficiency anemia (IDA).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading